Company intelligence
Greenstone Biosciences
Integrating AI/Machine learning with patient-derived stem cell technology to accelerate drug discovery.
About Greenstone Biosciences
Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation
Verified activity
Signals from Greenstone Biosciences
2 published signals
People
Greenstone Biosciences is hiring a motivated scientist to join the Palo Alto team for drug discovery using iPSCs, stem cell-derived models, and next-generation screening approaches.
Reported by Greenstone Biosciences
Research & Knowledge
Greenstone Biosciences published a study in Nature Biotechnology examining 2,310 individual cells from the developing human brain using label-free single-cell mass spectrometry to measure around 800 proteins in each cell.
Reported by Mukhtar Ahmed PhD